Aastrom Biosciences, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Private equity placement of 2.8 mil. shares of common stock raises $6 mil. to support clinical trial programs for the AastromReplicell cell production system and to expand operations. The financing is the second for the Ann Arbor, Michigan-based firm this year, with a total of about $12 mil. raised so far. The funds "have allowed us to resume our U.S. clinical trial programs and to initiate expanded operations," Aastrom says. "Additionally, we are now in position to resume pilot European marketing of the AastromReplicell system and to pursue application of our products and technologies into new therapy opportunities"